FLT3 inhibitors - their role in AML
What does epigenetics mean to CLL?
Potential clinical impact of genomic analysis in CLL
Highlights from EHA 2016 press briefings: Nivolumab, SGN-CD33A and hemophilia
Clinically relevant side effects of BiTE immunotherapy and other T-cell therapies